• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Biocon launches Tacrolimus capsules in US

expresspharmaDecember 29, 2020

Tag: Biocon , Tacrolimus Capsules , US , immunosuppressant , Organ transplant

Biocon announced the launch of Tacrolimus capsules in the US. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ.

It has been particularly effective in treating patients of renal transplant for more than two decades.

Siddharth Mittal, CEO and MD, Biocon, said, “The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients.”


Previous:LYNPARZA (olaparib) get three new approvals in Japan

Next:Serum Institute of India launches indigenously developed pneumococcal vaccine, ‘PNEUMOSIL’

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Biocon launches Tacrolimus capsules in US | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Reishi mushroom extract

Reishi mushroom extract
Tussilagone

Tussilagone
butyrospermum parkii powder Shea Butter powder Mimusops elengi powder avocado powder

butyrospermum parkii powder Shea Butter powder Mimusops elengi powder avocado powder
Astragalus Polysaccharides

Astragalus Polysaccharides
Tribulus Terrestris Extract

Tribulus Terrestris Extract
Ziziphus Jujube Extract Powder 10:1

Ziziphus Jujube Extract Powder 10:1
industrial cooling water DBNE(2,2-Dibromo-2-Nitroethanol)

industrial cooling water DBNE(2,2-Dibromo-2-Nitroethanol)
Cissus Qudrangularis extract

Cissus Qudrangularis extract
Pure Extract Phellinus linteus polysaccharides

Pure Extract Phellinus linteus polysaccharides
High quality free sample Industrial Grade Technical Grade In Organic Salt 98% Calcium Formate Powder

High quality free sample Industrial Grade Technical Grade In Organic Salt 98% Calcium Formate Powder

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service